IRAK1 and chronic myelogenous leukemia, BCR-ABL1 positive: The combination of imatinib and IRAK1/4 inhibitor, which deactivated NF-κB, attenuated PD-L1 expression on mouse and human CML LSCs compared with imatinib or IRAK1/4 inhibitor alone (Supplementary Fig. 4d–f).